$0.938
+0.004 (+0.40%)At close
NCNA News
NCNA Events
NuCana Secures Important Patent for NUC-7738 from EPO
NuCana announced that the European Patent Office, EPO, has granted an important patent covering the composition of matter for NUC-7738. This patent is a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition-of-matter patent covers the chemical structure of NUC-7738, NuCana's novel anti-cancer agent currently being evaluated in the Phase 2 part of a Phase 1/2 clinical study in combination with Keytruda in patients with PD-1 inhibitor-resistant metastatic melanoma.
NuCana Appoints Ian Webster as CFO
NuCana announced the appointment of Ian Webster as CFO, effective immediately. Ian has served as interim CFO since June 2025 and was previously director of finance since joining NuCana in 2019.
NuCana Appoints Theresa Bruce as COO Effective January 1, 2026
NuCana announced the appointment of Theresa Bruce as Chief Operating Officer, COO, effective January 1, 2026. Bruce previously served as Chief Operating Officer at Nexus Oncology
NuCana Presents NUC-7738 Clinical Data at ESMO Congress
NuCana presented the latest clinical data at the annual European Society for Medical Oncology, ESMO, Immuno-Oncology Congress, December 10-12, 2025, in London. The data from patients with PD-1 inhibitor-resistant metastatic melanoma treated with NUC-7738 in combination with pembrolizumab continue to demonstrate clinical activity and a favorable safety profile. All patients had progressive disease prior to starting treatment. Clinical activity includes two partial responses and seven cases of stable disease, notably including one ongoing stable disease converting to a complete metabolic response with no detectable active disease. These results further reinforce the initial findings presented at the ESMO Congress 2024.
NuCana Presents NUC-7738 Clinical Data at ESMO Congress
NuCana presented the latest clinical data at the annual European Society for Medical Oncology, ESMO, Immuno-Oncology Congress, December 10-12, 2025, in London. The data from patients with PD-1 inhibitor-resistant metastatic melanoma treated with NUC-7738 in combination with pembrolizumab continue to demonstrate clinical activity and a favorable safety profile. All patients had progressive disease prior to starting treatment. Clinical activity includes two partial responses and seven cases of stable disease, notably including one ongoing stable disease converting to a complete metabolic response with no detectable active disease. These results further reinforce the initial findings presented at the ESMO Congress 2024. As of the most recent analysis, nine patients have been treated in the Expansion Cohort, which is part of the planned enrollment of up to 28 additional patients. Combined with the 12 patients previously treated in the Dose Confirmation Cohort, this will provide a total combination dataset comprising up to 40 patients.
Related articles
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.